 |
|
|
| |
The Effect of Antiretroviral Therapy Without CCR5-Antagonists on HIV-1 Tropism in the MOTIVATE Studies of Maraviroc in Treatment-Experienced Patients With R5 HIV-1
|
| |
| |
Reported by Jules Levin
EACS Nov 13 2009 Cologne Germany
Perno CF1, Nelson M2, Waters L2, Clotet B3, Paredes R3, Heera J4, Mayer H5, Dang N6, Valdez H6, Zhen Luo7, Van Der Ryst E8
1University of Rome Tor Vergata, Italy
2Chelsea and Westminster Hospital, London, UK
3Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
4Pfizer Global R&D, New London, CT, USA
5Pfizer Inc, New York, NY, USA
6Pfizer Inc, Paris, France
7Pfizer Global R&D, Shanghai, China
8Pfizer Global R&D, Sandwich, UK
1Melby et al. J Infect Dis 2006; 194:238-246; 2Waters et al. 16th CROI, Montreal, Canada, 2009. Abstract 439a
1Berger et al. Annu Rev Immunol 1999; 17:657-700; 2Delobel et al. J Acquir Immune Defic Syndr. 2005;38:382-92; 3Soulié et al. AIDS 2007;21:2243-5; 4 Melby et al. J Infect Dis. 2006;194:238-246;
1Gulick et al. N Engl J Med. 2008;359:1429-1441
1Gulick et al. N Engl J Med. 2008;359:1429-1441
|
| |
|
|
|
|
|
